Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$17.24
+2.4%
$12.65
$7.08
$17.35
$355.67M0.8282,437 shs27,688 shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$13.61
+4.5%
$14.51
$10.60
$38.12
$1.43B0.251.19 million shs110,943 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$10.49
+0.4%
$11.26
$5.78
$22.00
$1.34B2.39282,950 shs28,440 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$15.98
+4.5%
$16.53
$7.93
$25.29
$1.41B0.721.61 million shs252,305 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
+1.08%+0.12%+32.31%+83.61%+13.78%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
+3.25%+1.56%-14.57%+4.16%-37.76%
Mesoblast Limited stock logo
MESO
Mesoblast
-0.76%-13.78%-11.37%-5.69%+35.19%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+4.79%+4.01%-0.13%+6.62%+75.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amarin Corporation PLC stock logo
AMRN
Amarin
0.6044 of 5 stars
0.55.00.00.02.20.00.6
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.6375 of 5 stars
3.43.00.00.02.62.50.0
Mesoblast Limited stock logo
MESO
Mesoblast
1.9811 of 5 stars
3.51.00.00.02.50.80.6
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
3.3292 of 5 stars
4.43.00.00.02.40.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.00
Sell$12.00-28.70% Downside
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.80
Moderate Buy$40.00207.22% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
3.00
Buy$18.0072.25% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.87
Moderate Buy$32.14110.08% Upside

Current Analyst Ratings Breakdown

Latest AMRN, MESO, EWTX, and TVTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$30.00
6/30/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$42.00
6/25/2025
Amarin Corporation PLC stock logo
AMRN
Amarin
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$7.00 ➝ $12.00
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$30.00
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$35.00 ➝ $32.00
6/5/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$48.00
5/16/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/16/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
5/2/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.00
5/2/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$22.00 ➝ $23.00
4/30/2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$41.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$228.61M1.52N/AN/A$23.62 per share0.71
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.84 per shareN/A
Mesoblast Limited stock logo
MESO
Mesoblast
$5.90M226.32N/AN/A$4.21 per share2.48
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$233.18M5.83N/AN/A$0.76 per share20.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$82.18M-$3.64N/AN/AN/A-41.07%-17.21%-12.16%7/30/2025 (Estimated)
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$133.81M-$1.55N/AN/AN/AN/A-30.95%-29.45%8/6/2025 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$321.55M-$2.81N/AN/AN/A-82.88%-1,179.73%-41.10%7/30/2025 (Estimated)

Latest AMRN, MESO, EWTX, and TVTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.60N/AN/AN/A$45.45 millionN/A
5/8/2025Q1 2025
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.45-$0.43+$0.02-$0.43N/AN/A
5/7/2025Q1 2025
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A
5/1/2025Q1 2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.53
2.55
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
20.99
20.99
Mesoblast Limited stock logo
MESO
Mesoblast
0.22
0.96
0.63
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9.46
2.05
2.03

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
1.96%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
23.20%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
36020.71 million20.30 millionOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
60105.20 million80.79 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
80127.78 million103.76 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46088.81 million85.20 millionOptionable

Recent News About These Companies

Q2 EPS Estimate for Travere Therapeutics Lowered by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$17.24 +0.41 (+2.42%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$13.61 +0.59 (+4.53%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$10.49 +0.04 (+0.37%)
As of 11:00 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$15.98 +0.68 (+4.45%)
As of 11:01 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.